Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample
PLOS ONE · 2024
DOI: 10.1371/journal.pone.0313660 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Karen M Stockl und 5 weiteren Autor:innen. Beteiligte Einrichtung: Optum, Eden Prairie, Minnesota, United States of America. Hauptthemen laut MEDLINE: COVID-19, Influenza, Human, Outpatients, SARS-CoV-2. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cepheid.
Abstract (Originalsprache)
While molecular testing is recommended for symptomatic patients suspected of having coronavirus disease 2019 (COVID-19), limited data are available examining real-world use of tests for severe acute respiratory syndrome coronavirus (SARS-CoV-2) and the impact of SARS-CoV-2 testing on patient outcomes. In this retrospective cohort study using de-identified administrative claims data in the Optum Labs Data Warehouse, we identified 2 groups of patients with ≥1 outpatient claims with a procedure code for SARS-CoV-2 testing between January 2021 and September 2022. Group 1 had ≥1 claims with CPT code 0240U or 0241U (“Xpert Xpress”) (N = 51,602); Group 2 had ≥1 claims for laboratory-based molecular testing (N = 317,192). Outcomes assessed on the identification date and through the 90-day follow-up included claims evidence of use of SARS-CoV-2, influenza, and respiratory syncytial virus (RSV) tests, diagnosis of active COVID-19, influenza, or RSV, and use of treatments (antivirals for COVID-19, influenza, and RSV and other treatments for COVID-19 and RSV). Patients in Group 1 had fewer tests for SARS-CoV-2, influenza, or RSV (mean ± standard deviation 1.6±1.4 versus 2.6±2.6, standardized difference -0.45), faster time to diagnosis of COVID-19 (median 0 versus 4 days, standardized difference -0.27) or influenza (median 0 versus 5 days, standardized difference -0.74), and faster time to treatment of COVID-19, influenza, or RSV (median 1 versus 5 days, standardized difference 0.16) than patients in Group 2. In this nationwide real-world study of outpatient testing, use of point-of-care molecular multiplex SARS-CoV-2 testing resulted in fewer claims for SARS-CoV-2, influenza, and RSV tests, faster time to diagnosis, and faster time to treatment than laboratory-based molecular testing.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Optum, Eden Prairie, Minnesota, United States of America.
- Cepheid, Sunnyvale, California, United States of America.
ORCID-Profile: Jamie Tucker, Julia M Certa, Jordan G Chase
Förderung
- Cepheid
Zitieren
APA
Stockl, K. M., Tucker, J., Beaubrun, A., Certa, J. M., Becker, L., & Chase, J. G. (2024). Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample. PLOS ONE. https://doi.org/10.1371/journal.pone.0313660
Vancouver
Stockl KM, Tucker J, Beaubrun A, Certa JM, Becker L, Chase JG. Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample. PLOS ONE. 2024. doi:10.1371/journal.pone.0313660
BibTeX
@article{Stockl2024,
author = {Stockl, Karen M and Tucker, Jamie and Beaubrun, Anne and Certa, Julia M and Becker, Laura and Chase, Jordan G},
title = {Real-world use of multiplex point-of-care molecular testing or laboratory-based molecular testing for influenza-like illness in a 2021 to 2022 US outpatient sample},
journal = {PLOS ONE},
year = {2024},
doi = {10.1371/journal.pone.0313660}
}
EUVIMED